Sentences with phrase «on availability of funds»

Additional funding will depend on the availability of funds.

It is permissible for adoptive parents & Expedited Kinship Foster Parents to make application for assistance; however, these determinations will be made on a case - bycase basis, based on availability of funds and present circumstances.

The National Adoption Foundation offers $ 500 - 2,500 grants to adoptive families based on the availability of funds.

«We are proud to be the first bank to use Ripple's leading Blockchain network solution to power real - time payments between Japan and Thailand for our customers, whose families oftentimes depend on the availability of these funds for basic needs — time is of the essence to them.

The bicycles among APL and general girls are distributed by the State HRD but the distribution among all the school going girls would be taken on availability of funds with the Human Resource department.

However, we are funded by private donations and grant money so our ability to subsidize always depends on availability of funds and time of year.

These funds are deposited into the Pet Overpopulation Fund, on a quarterly basis, where they are then distributed to qualified veterinary clinics and humane societies through grants once or twice a year, based on the availability of funds.

It depends on the availability of funds and the internal policy of the fund house on dividend declaration.

They buy the stocks on the availability of funds.

However, we may apply additional delays on the availability of funds based on any other factors as determined by us, in our sole discretion.

Each bank has its own policies on the availability of funds.

The maximum grant award per school is $ 1,400 annually, contingent on the availability of funds.

But the permanent positions that are supposed to come at the end of the track depend on the availability of funds.

The Syracuse Common Council has proposed loaning the newly formed city - county land bank money so it can begin operating in earnest, but questions remain on the availability of those funds.

The outcomes of this article published this week in PNAS, Proceedings of the National Academy of Sciences, raise several questions some of which are expected to be immediately dealt with, although dependent on the availability of funding.

Those proposals, however, are contingent on the availability of funding.

In that and the following two years, Ford began mapping the centre, but further research depends on the availability of funding.

In a previous column I discussed how money from overseas is having a powerful impact on the availability of funding for new development here in the U.S., and is extending the nation's economic recovery.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Among the possible negatives: A combination of higher transaction fees, a tiering of the interest rate based on the size of the account, and reduced funds availability on deposits.

Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, and capital markets conditions and other factors beyond the Company's control, including natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2) the Company's credit ratings and its cost of capital; (3) competitive conditions and customer preferences; (4) foreign currency exchange rates and fluctuations in those rates; (5) the timing and market acceptance of new product offerings; (6) the availability and cost of purchased components, compounds, raw materials and energy (including oil and natural gas and their derivatives) due to shortages, increased demand or supply interruptions (including those caused by natural and other disasters and other events); (7) the impact of acquisitions, strategic alliances, divestitures, and other unusual events resulting from portfolio management actions and other evolving business strategies, and possible organizational restructuring; (8) generating fewer productivity improvements than estimated; (9) unanticipated problems or delays with the phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company's information technology infrastructure; (10) financial market risks that may affect the Company's funding obligations under defined benefit pension and postretirement plans; and (11) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10 - K for the year ended Dec. 31, 2017, and any subsequent quarterly reports on Form 10 - Q (the «Reports»).

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

In addition to factors previously disclosed in Tesla's and SolarCity's reports filed with the U.S. Securities and Exchange Commission (the «SEC») and those identified elsewhere in this document, the following factors, among others, could cause actual results to differ materially from forward - looking statements and historical performance: the ability to obtain regulatory approvals and meet other closing conditions to the transaction, including requisite approval by Tesla and SolarCity stockholders, on a timely basis or at all; delay in closing the transaction; the ultimate outcome and results of integrating the operations of Tesla and SolarCity and the ultimate ability to realize synergies and other benefits; business disruption following the transaction; the availability and access, in general, of funds to meet debt obligations and to fund ongoing operations and necessary capital expenditures; and the ability to comply with all covenants in the indentures and credit facilities of Tesla and SolarCity, any violation of which, if not cured in a timely manner, could trigger a default of other obligations under cross-default provisions.

The amount you can borrow depends on your financial need, the amount of other aid you receive, and the availability of funds at your college or career school.

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

Examples of these risks, uncertainties and other factors include, but are not limited to the impact of: adverse general economic and related factors, such as fluctuating or increasing levels of unemployment, underemployment and the volatility of fuel prices, declines in the securities and real estate markets, and perceptions of these conditions that decrease the level of disposable income of consumers or consumer confidence; adverse events impacting the security of travel, such as terrorist acts, armed conflict and threats thereof, acts of piracy, and other international events; the risks and increased costs associated with operating internationally; our expansion into and investments in new markets; breaches in data security or other disturbances to our information technology and other networks; the spread of epidemics and viral outbreaks; adverse incidents involving cruise ships; changes in fuel prices and / or other cruise operating costs; any impairment of our tradenames or goodwill; our hedging strategies; our inability to obtain adequate insurance coverage; our substantial indebtedness, including the ability to raise additional capital to fund our operations, and to generate the necessary amount of cash to service our existing debt; restrictions in the agreements governing our indebtedness that limit our flexibility in operating our business; the significant portion of our assets pledged as collateral under our existing debt agreements and the ability of our creditors to accelerate the repayment of our indebtedness; volatility and disruptions in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; fluctuations in foreign currency exchange rates; overcapacity in key markets or globally; our inability to recruit or retain qualified personnel or the loss of key personnel; future changes relating to how external distribution channels sell and market our cruises; our reliance on third parties to provide hotel management services to certain ships and certain other services; delays in our shipbuilding program and ship repairs, maintenance and refurbishments; future increases in the price of, or major changes or reduction in, commercial airline services; seasonal variations in passenger fare rates and occupancy levels at different times of the year; our ability to keep pace with developments in technology; amendments to our collective bargaining agreements for crew members and other employee relation issues; the continued availability of attractive port destinations; pending or threatened litigation, investigations and enforcement actions; changes involving the tax and environmental regulatory regimes in which we operate; and other factors set forth under «Risk Factors» in our most recently filed Annual Report on Form 10 - K and subsequent filings by the Company with the Securities and Exchange Commission.

All Grant - In - Aids are awarded on the basis of need and availability of Grant - In - Aid funds at the time of application.

The added competition for retail funds from NS&I not only distorts the savings market, but increases the cost and reduces the availability of mortgage funding which building societies and other lenders rely on for mortgage lending.

«We are pleased to be an investment partner with the Community Preservation Corporation on this shared mission to help revitalize New York's communities and increase the availability of affordable housing,» said New York State Comptroller Thomas P. DiNapoli, trustee of the New York state pension fund.

New York state Gov. Andrew Cuomo announced the availability of $ 150 million in state funds on Thursday that will support large - scale renewable energy projects.

Poughkeepsie... Dutchess County Executive Marcus J. Molinaro has announced the availability of funding to help senior citizens complete minor to moderate rehabilitation on their homes.

Acceptance of applications is also subject to availability of funds on the application date.

Beyond the payroll tax and charitable donation programs, Cuomo offered up ideas to reduce traffic congestion in New York City, expand availability of flu vaccines for children, impose restrictions on sex offenders, provide funding for an early voting program, ban synthetic marijuana sales and target physicians who engage in medical misconduct.

Such assistance is based on assessment of need and availability of program funds.

Last week, NSERC President Tom Brzustowski posted a memo on the organization's Web site, stating that NSERC «can not assure the availability of funds for successful applications for Major Installations, Major Equipment, or regular equipment (now called Research Tools and Instruments) in the upcoming competition.»

Once a drug is developed and on the market what the Global Fund does is try to improve access to that drug for the poorest of poor by using advance purchasing or using commitments to try to ensure the availability of that drug on a large scale.

The INF project will provide data archival and access function for compliance to DFG regulations on availability of data generated in DFG - funded projects.

The position will be initially offered for two years and further continuation are based on satisfactory performance and availability of funds.

Enhancing the development of innovative translational researchers in endometrial cancer is critically dependent on the availability of flexible funding for career enhancement projects.

The postdoctoral posts are available for a fixed term of 1 year with a possible extension of up to 3 years, depending on performance and funding availability.

The selection of participants is based on academic records; letters of recommendation; science and engineering background; interests and professional goals; statement of research to be performed; compatibility of research interests with the sponsor's research programs and resources; and availability of funds, staff, programs, and equipment.

This work is part of a newly funded U.S. Department of Energy / Department of Agriculture project led by the University of Missouri, Columbia to explore the biology of a single plant cell type, while gaining novel insight into the impacts of temperature and water availability on a crucial root cell necessary for nutrient uptake.

The duration of the fellowship is up to three years: an initial one - year appointment, and two annual renewals, contingent on satisfactory performance and availability of NASA funds.

FLORENCE, Italy — With its national banks teetering on the edge of default and an uncertain economic future, Italy's financial woes have had a significant impact on state funding for arts education and the availability of student finance for Italian students, creating a challenging landscape for fashion education.

While the issues at stake vary by state, a number of elections this cycle will hinge on a variety of education - related questions, including recent cuts to public schools, growing class sizes, Common Core State Standards, access to pre-K education and the availability of state - funded student loans for college.

Topics addressed include the obligation of schools to recommend programs and services based on student need regardless of availability in the building, funding, staffing, space and other considerations; the role of School Implementation Teams (SITs); participation in IEP team meetings; Chapter 408 requirements and a number of issues related to integrated co-teaching services.

Policy leaders, in particular, can (1) support initiatives that expand broadband availability in all of the federally funded 21st Century Community Learning Centers and in state and locally - funded afterschool sites; (2) encourage robust experimentation with digital platforms that allow expanded learning organizations to collaborate, share practices, and connect experiences that kids are having at various expanded learning sites; and (3) support pilot experiments in up to 10 % of the 21st Century Community Learning Centers that focus on integrating evolving technologies.

WASHINGTON — U.S. Transportation Secretary Anthony Foxx today announced the immediate availability of $ 1 million in Emergency Relief (ER) funds from the Federal Highway Administration (FHWA) to help begin repairs on flood - damaged roads and bridges in north and central Pennsylvania.

On July 31, 2012, DOT published a Notice of Funding Availability (NOFA) in the Federal Register that outlines the credit assistance review process and invites project sponsors to submit a letter of interest (LOI) for TIFIA credit assistance on a rolling basiOn July 31, 2012, DOT published a Notice of Funding Availability (NOFA) in the Federal Register that outlines the credit assistance review process and invites project sponsors to submit a letter of interest (LOI) for TIFIA credit assistance on a rolling basion a rolling basis.

The Notice of Funding Availability (NOFA), published on March 11, 2016, outlines the process that applicants must follow.